Cargando…

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives

Recently, the global incidence of gastric/gastroesophageal junction (G/GEJ) cancer has remained high. China is also a large country with a high gastric cancer (GC) incidence rate, where the cases of GC account for 40% of all cases worldwide. More than 90% of GEJ cancers are the adenocarcinoma pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Weiling, Zhang, Xiaoling, Du, Yunyi, Zhang, Ying, Lu, Jing, Hu, Wenqing, Zhao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524015/ https://www.ncbi.nlm.nih.gov/pubmed/36175985 http://dx.doi.org/10.1186/s40364-022-00416-x

Ejemplares similares

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
por: Lago, Nieves Martínez, et al.
Publicado: (2020)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
por: Esen, Selin Aktürk, et al.
Publicado: (2022)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
por: Shan, Ling, et al.
Publicado: (2013)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
por: Zhang, Zhening, et al.
Publicado: (2020)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma
por: Brotherton, Tim, et al.
Publicado: (2022)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma
por: Nakayama, I., et al.
Publicado: (2023)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study
por: Huang, Dan, et al.
Publicado: (2013)

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel
por: BAR-SELA, GIL, et al.
Publicado: (2013)

Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population
por: Roy, Partha S, et al.
Publicado: (2019)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
por: Shen, Bo, et al.
Publicado: (2020)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
por: Manfredi, Sylvain, et al.
Publicado: (2022)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
por: Kundel, Yulia, et al.
Publicado: (2020)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
por: Schulz, Christoph, et al.
Publicado: (2020)

Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
por: Perkhofer, Lukas, et al.
Publicado: (2019)

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
por: Businello, Gianluca, et al.
Publicado: (2022)

Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
por: Dai, Shu-Qin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s9crdifudrrciv8s7te9lde4h4